Absci vs iBio
ABSI and IBIO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABSI and IBIO compare
Absci is the larger company, worth 31 times as much as iBio ($1.5B against $47.1M).
iBio grew revenue faster over the last twelve months (115% versus −47.2% for Absci).
iBio keeps more of each dollar of sales as profit, with a net margin of −3244% compared with −8451% at Absci.
iBio scores higher on the StockData Score (9 against 5 for Absci), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABSI | IBIO |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $47.1M |
| Share price | $8.45 | $0.732 |
| Change, 1 year | 149% | −41.5% |
| Change, 5 years | −23.5% | −99.8% |
| Beta (5Y) | 2.19 | 1.12 |
| Employees | 140 | 23 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 975× | 43.8× (better) |
| P/B | 6.6× | 0.6× (better) |
| FCF yield | −7.8% (better) | −58.6% |
| Growth | ||
| Revenue growth (TTM) | −47.2% | 115% (better) |
| Revenue growth, 5Y average | −10.1% (better) | −46.9% |
| Profitability | ||
| Operating margin | −8812% | −3491% (better) |
| Net margin | −8451% | −3244% (better) |
| FCF margin | −7563% | −2566% (better) |
| Return on equity | −58.6% | −51.8% (better) |
| Return on invested capital | −242% (better) | −728% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −2569.4× | – |
| Current ratio | 9.64 (better) | 9.48 |
| Altman Z-score | 36.44 (better) | −3.49 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −7.6% | – |
| Shareholder yield | −7.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 88.3% | 54.0% |
| Held by insiders | 15.5% | 0.47% |
| Insider net buying, 12 months | $801K (better) | $98.1K |
| Short interest, % of float | 24.7% | 6.3% |
Go deeper
- ABSI stock overview
- ABSI income statement
- ABSI valuation and score
- IBIO stock overview
- IBIO income statement
- IBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.